Venture Capital

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

Tokyo-based materials giant DIC is investing $62M in Physical AI, partnering with a Swiss VC to bridge the gap between the digital and physical worlds.

Top policymakers, including Dr. Agustín Carstens and FATF President Luis Urrutia Corral, will convene in Mérida to address critical cross-border tax issues.

NFL star Shawne Merriman alleges his lender is attempting a hostile takeover of his company, sparking a high-stakes legal battle over corporate control.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

Cohen & Co.-backed SPAC joins the hunt for a merger target, highlighting a renewed investor appetite for blank check companies in a maturing market.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

The SaaS firm posts strong net income and recurring revenue growth from its B2B platform, offsetting a decline in its transactional business.

A mid-market bank's AI deal reveals a larger trend: how specialized financiers are becoming the crucial, unseen engine behind tech's next evolution.

With $18M in grants, Reed Jobs's Yosemite uses a novel blend of philanthropy and VC to bridge critical funding gaps in the fight against cancer.

Public market giant Seligman Investments launches a venture arm with a seasoned team to invest in the foundational tech of tomorrow's economy.

CRB appoints veteran John R. Lupa, Jr. to spearhead national construction, a strategic move to dominate the booming life sciences and food facility market.

Hong Kong's exchange appoints Jalal Almarhoon to spearhead its Riyadh office, signaling a major strategic move to link Asian and Middle Eastern capital.

Proem Acquisition Corp I launches a $130M IPO, led by tech IPO guru Imran Khan. But can it succeed in a revived, yet risk-laden, SPAC landscape?

The Investment Company Institute is linking its industry to America's 250th birthday. Is it a genuine celebration or a strategic rebrand?

Lincoln International data reveals slowing growth and rising debt distress in private companies, a stark contrast to the heated M&A market for top assets.